Considering that RANK inhibition was demonstrated to improve immune responses the combination of RANK inhibitors, e.g., denosumab, with checkpoint inhibitors may be worth to assess in clinical trials of OC and other gynaecological malignancies, such as cervical cancer, which was shown also to be of high expression of RANK and RANKL [46]. This evidence concerns the gene TNFRSF11A and cervical cancer.